MLTX
MoonLake ImmunotherapeuticsCompany with tickers: MLTX
CIK
1821586
CUSIP
61559X104
Shares Outstanding
73,615,396
Website
https://www.moonlaketx.com
13F Activity (30d)
5 filings
3 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $70,024,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Research & Development | $54,515,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Operating Income | $-70,024,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Net Income | $-69,707,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Basic) | $-0.98 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Diluted) | $-0.98 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |